Esra SAATÇİ, Yüksel KOÇAK, Nafiz BOZDEMİR, Ersin AKPINAR, Zeynep KALAYLIOĞLU-WHEELER

Effect of chemotherapy on quality of life in patients with lymphoma

Amaç: Kemoterapideki gelişmeler lenfomalı hastaların yaşam sürelerini önemli derecede uzatmıştır ve önemli sayıda hasta tedavi edilebilmektedir. Kemoterapi alan hastaların yaşam kalitelerinin değerlendirilmesi giderek daha fazla ilgi çeken bir konu olmuştur. Çalışmamızın amacı, lenfomalı hastalarda kemoterapinin yaşam kalitesine etkilerini değerlendirmektir. Gereç ve Yöntem: Haziran 2000-Ocak 2001 tarihleri arasında Çukurova Üniversitesi Tıp Fakültesi Onkoloji Bilim Dalı’nda Evre I lenfoma tanısı alan 49 hastaya kemoterapi öncesinde ve 2. kür sonrasında yaşam kalitesi anketi (EORTC QLQ C-30) uygulandı. Bulgular: Fiziksel aktivitelerin bazılarında, duygusal fonksiyonlar, ağrı ve halsizlik, dispne, iştahsızlık, uyku ve global yaşam kalitesinde tedavi sırasında anlamlı iyileşme saptandı. Kemoterapi, yaş, cinsiyet ve lenfoma tipi göz önüne alındığında, global yaşam kalitesini etkileyen en önemli faktör hastanın eğitim durumuydu. Sonuç: Çalışmamızın sonuçları, kemoterapi öncesindeki yaşam kalitesine kıyasla tedavi sonrası yaşam kalitesinde iyileşme olması nedeniyle, kemoterapi alma konusunda isteksiz olan hastalara yardımcı olmada kullanılabilir.

Lenfomalı hastalarda kemoterapinin yaşam kalitesine etkisi

Aim: Advances in chemotherapy have significantly prolonged survival of patients with lymphoma and a significant percentage of patients may be cured. The assessment of the quality of life in patients undergoing chemotherapy is of growing interest. The aim of this study is to assess the effect of chemotherapy on quality of life in patients with lymphoma. Methods: All patients (n=49) diagnosed with stage I lymphoma in the Cukurova University Oncology Department from June 2000 to January 2001 received a quality-of-life questionnaire (EORTC QLQ C-30) before chemotherapy and after the second cycle of chemotherapy. Results: Significant improvement during treatment was found in some of the physical activities, emotional functioning, relieve from pain and fatigue, dyspnea, anorexia, sleep, and global quality of life. When chemotherapy, age, gender and lymphoma type were taken into account, the most important factor influencing the global quality of life was educational status. Conclusion: The results may be used to reassure the patients who are reluctant to go through chemotherapy that they are likely to experience an improved quality of life compared to their situation before the treatment.

PDF

___

1) Guyatt G, Veldhuyzen Van Zanten S, Feeny D, Patrick D. Measuring quality of life in clinical trials: a taxonomy and review. Can Med Assoc J 1989; 140: 1441-1448.
2) Lauper P, Versteegen U. The importance of quality of life in policy decisions: new end points in medical outcome assessment. Pharm Med 1992; 5: 43-50.
3) Schumacher A, Kessler T, Riedel A, Buchner T, van de Loo J. Quality of life and coping with illness in patients with acute myeloid leukemia. Psychother Psychosom Med Psychol 1996; 46: 385-390.
4) Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Medical Oncology 2001; 18: 85-94.
5) Persson L, Larsson G, Ohlsson O, Hallberg IR. Acute leukemia or highly malignant lymphoma patients’ quality of life over two years: a pilot study. Eur J of Cancer Care 2001; 10: 36-47.
6) Cella DF, Tulsky S. Measuring quality of life today: methodological aspects. Oncology 1990; 4: 29-38.
7) The WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-1409.
8) Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992; 84: 575-579.
9) Cella DF. Quality of life: the concept. J Palliat Care 1992; 8: 8-13.
10) Kaasa S, Loge JH. Quality of life in palliative care: principles and practice. Palliat Med 2003; 17: 11-20.
11) Wierzbicka M, Kusnierkiewicz M, Wojtowicz JG, Maune S, Szyfter W. The quality of life in head and neck cancer patients: description of randomized examination formula based on standardized questionnaires EORTC QLQ C-30, EORTC QTQ-H-N35 and Kiel Questionnaire. Otolaryngol Pol 2001; 55: 287-292 [in Polish].
12) Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analyzed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-2263.
13) Kobayashi K, Takeda F, Teramukai S, Gotah I, Sakai H, Yoneda S et al. A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 1998; 34: 810–815.
14) Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997; 6: 103-108.
15) Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
16) Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 1994; 33: 879-885.
17) Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36: 1796-1807.
18) Blazeby JM, Alderson D, Winstone K, Steyn R, Hammerlid E, Arraras J et al. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group. Eur J Cancer 1996; 32A: 1912-1917.
19) Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998; 7: 291-300.
20) Schumacher A, Kessler T, Buchner T, Wewers D, van de Loo J. Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy-a longitudinal study. Leukemia 1998; 12: 586-592.
21) Ruffer JU, Flechtner H, Tralls P, Josting A, Sieber M, Lathan B et al. Fatigue in long-term survivors of Hodgkin‘s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003; 39: 2179-2186.
22) Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34: 4-12.
23) Curt GA. The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 2000; 5 (Suppl 2): 9-12.